These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28036286)

  • 1. HER3 and LINC00052 interplay promotes tumor growth in breast cancer.
    Salameh A; Fan X; Choi BK; Zhang S; Zhang N; An Z
    Oncotarget; 2017 Jan; 8(4):6526-6539. PubMed ID: 28036286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer.
    Zhang S; Mukherjee S; Fan X; Salameh A; Mujoo K; Huang Z; Li L; To'a Salazar G; Zhang N; An Z
    Oncotarget; 2016 Oct; 7(40):65758-65769. PubMed ID: 27582551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NRG-1 Stimulates Serum DJ-1 Increase in Breast Cancers.
    Wang Y; Zhang Y; Lu Q; Wang Y; Sun X; Zhang S
    Pathol Oncol Res; 2019 Jan; 25(1):71-79. PubMed ID: 28963699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers.
    Li X; Duan Y; Qiao C; Zhou T; Yu M; Geng J; Feng J; Shen B; Lv M; Li Y
    Technol Cancer Res Treat; 2016 Aug; 15(4):573-82. PubMed ID: 26041400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.
    Ren XR; Wang J; Osada T; Mook RA; Morse MA; Barak LS; Lyerly HK; Chen W
    Breast Cancer Res; 2015 Feb; 17(1):20. PubMed ID: 25849870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decoding LINC00052 role in breast cancer by bioinformatic and experimental analyses.
    Sanchez-Lopez JM; Juarez-Mancera MA; Bustamante B; Ruiz-Silvestre A; Espinosa M; Mendoza-Almanza G; Ceballos-Cancino G; Melendez-Zajgla J; Maldonado V; Lizarraga F
    RNA Biol; 2024 Jan; 21(1):1-11. PubMed ID: 38832821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.
    Morrison MM; Hutchinson K; Williams MM; Stanford JC; Balko JM; Young C; Kuba MG; Sánchez V; Williams AJ; Hicks DJ; Arteaga CL; Prat A; Perou CM; Earp HS; Massarweh S; Cook RS
    J Clin Invest; 2013 Oct; 123(10):4329-43. PubMed ID: 23999432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER3 Is an Actionable Target in Advanced Prostate Cancer.
    Gil V; Miranda S; Riisnaes R; Gurel B; D'Ambrosio M; Vasciaveo A; Crespo M; Ferreira A; Brina D; Troiani M; Sharp A; Sheehan B; Christova R; Seed G; Figueiredo I; Lambros M; Dolling D; Rekowski J; Alajati A; Clarke M; Pereira R; Flohr P; Fowler G; Boysen G; Sumanasuriya S; Bianchini D; Rescigno P; Aversa C; Tunariu N; Guo C; Paschalis A; Bertan C; Buroni L; Ning J; Carreira S; Workman P; Swain A; Califano A; Shen MM; Alimonti A; Neeb A; Welti J; Yuan W; de Bono J;
    Cancer Res; 2021 Dec; 81(24):6207-6218. PubMed ID: 34753775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
    Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
    Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3.
    Rau A; Lieb WS; Seifert O; Honer J; Birnstock D; Richter F; Aschmoneit N; Olayioye MA; Kontermann RE
    Mol Cancer Ther; 2020 Jul; 19(7):1474-1485. PubMed ID: 32430487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
    Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
    Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing human epidermal growth factor receptor-3 radiosensitizes human luminal A breast cancer cells.
    He G; Di X; Yan J; Zhu C; Sun X; Zhang S
    Cancer Sci; 2018 Dec; 109(12):3774-3782. PubMed ID: 30259607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.
    Li W; Zhai L; Wang H; Liu C; Zhang J; Chen W; Wei Q
    Oncotarget; 2016 May; 7(19):27778-86. PubMed ID: 27034004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.
    Ogier C; Colombo PE; Bousquet C; Canterel-Thouennon L; Sicard P; Garambois V; Thomas G; Gaborit N; Jarlier M; Pirot N; Pugnière M; Vie N; Gongora C; Martineau P; Robert B; Pèlegrin A; Chardès T; Larbouret C
    Cancer Lett; 2018 Sep; 432():227-236. PubMed ID: 29935372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation.
    Zhao Z; Li R; Sha S; Wang Q; Mao W; Liu T
    Cancer Biol Ther; 2014 Oct; 15(10):1404-12. PubMed ID: 25046105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors.
    Aurisicchio L; Marra E; Luberto L; Carlomosti F; De Vitis C; Noto A; Gunes Z; Roscilli G; Mesiti G; Mancini R; Alimandi M; Ciliberto G
    J Cell Physiol; 2012 Oct; 227(10):3381-8. PubMed ID: 22213458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation.
    Mirschberger C; Schiller CB; Schräml M; Dimoudis N; Friess T; Gerdes CA; Reiff U; Lifke V; Hoelzlwimmer G; Kolm I; Hopfner KP; Niederfellner G; Bossenmaier B
    Cancer Res; 2013 Aug; 73(16):5183-94. PubMed ID: 23780344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.